Innodata (INOD) Stock Jumps 14.4%: Will It Continue to Soar? — Positive
INOD Zacks Investment Research — January 30, 2026Innodata (INOD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Vistra vs. Public Service Enterprise: Which Utility Stock Stands Out? — Positive
PEG VST Zacks Investment Research — January 30, 2026VST and PEG continue to efficiently serve their customers, the power generated from the nuclear power plants allows them to provide a large volume of emission-free electricity.
What Makes Lincoln Educational Services (LINC) a Good Fit for 'Trend Investing' — Positive
LINC Zacks Investment Research — January 30, 2026Lincoln Educational Services (LINC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Alpha and Omega (AOSL) — Positive
AOSL Zacks Investment Research — January 30, 2026Alpha and Omega (AOSL) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Recent Price Trend in Mama's Creations, Inc. (MAMA) is Your Friend, Here's Why — Positive
MAMA Zacks Investment Research — January 30, 2026Mama's Creations, Inc. (MAMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Cimpress (CMPR) Is a Great Choice for 'Trend' Investors, Here's Why — Positive
CMPR Zacks Investment Research — January 30, 2026If you are looking for stocks that are well positioned to maintain their recent uptrend, Cimpress (CMPR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Momentum in Forum Energy (FET) Should Keep going — Positive
FET Zacks Investment Research — January 30, 2026If you are looking for stocks that are well positioned to maintain their recent uptrend, Forum Energy (FET) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar — Positive
EQIX SPGI Zacks Investment Research — January 30, 2026The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Sunoco LP (SUN) Is a Great Choice for 'Trend' Investors, Here's Why — Positive
SUN Zacks Investment Research — January 30, 2026Sunoco LP (SUN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Why Fast-paced Mover Jabil (JBL) Is a Great Choice for Value Investors — Positive
JBL Zacks Investment Research — January 30, 2026If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Jabil (JBL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Celestica: A 2026 AI Opportunity With Growth Potential — Positive
CLS Seeking Alpha — January 30, 2026Celestica Inc. delivered robust Q4 results on Wednesday, driven by surging Data Center hardware demand from hyperscalers. The firm's total revenue reached $3.65B in Q4'25, up 44% year-over-year, with gross profits growing even faster at 46% Y/Y. CLS growth is tightly linked to hyperscaler CapEx cycles, benefiting from AI-driven infrastructure up-grades by major tech firms.
Altria stock (NYSE: MO) dropped 5% after a Q4 earnings miss. Although revenue (excluding excise taxes) surpassed expectations at $5.08 billion compared to the $5.02 billion estimate, the adjusted EPS of $1.30 fell short of the $1.32 consensus.
Viking Therapeutics to Report Q4 Earnings: Here's What to Know — Positive
VKTX Zacks Investment Research — January 30, 2026VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.
Transdigm to Report Q1 Earnings: Here's What You Need to Know — Positive
TDG Zacks Investment Research — January 30, 2026TDG's fiscal Q1 earnings are expected to benefit from Simmonds acquisition, rising aftermarket and defense demand boosting results.
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? — Positive
BMY Zacks Investment Research — January 30, 2026BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.
Serve Robotics vs. Teradyne: Which Robotics Stock Is the Better Buy? — Positive
SERV TER Zacks Investment Research — January 30, 2026Automation and robotics are steadily moving from experimentation into real-world deployment as advances in AI, compute and machine intelligence intersect with labor constraints and rising efficiency demands. Within this shifting landscape, Serve Robotics Inc. SERV and Teradyne, Inc. TER represent two very different ways for investors to gain exposure to the same long-term automation megatrend.
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU — Neutral
PLX GlobeNewsWire — January 30, 2026Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU — Neutral
PLX GlobeNewsWire — January 30, 2026Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026
Why Investors Rewarded Meta and Tesla But Punished Microsoft Despite Revenue Beat — Positive
MSFT 24/7 Wall Street — January 30, 2026Three mega-cap tech companies reported earnings on Wednesday, and the market's verdict was swift and brutal for one company while two Magnificent 7 members received stamps of approval.
Lumen to Report Q4 Earnings: Here's What Investors Should Know — Neutral
LUMN Zacks Investment Research — January 30, 2026LUMN heads into Q4 earnings with AI-fueled PCF momentum, rising NaaS adoption and cost cuts amid ongoing legacy revenue pressure.
